



EDUCATIONAL OBJECTIVE: Readers will prescribe beta-blockers as antihypertensive therapy only when there are compelling indications for them or as add-on treatment

QI CHE, MD, PhD

Department of Nephrology
and Hypertension, Glickman Urological
and Kidney Institute, Cleveland Clinic

MARTIN J. SCHREIBER, JR, MD

Chairman, Department of Nephrology and
Hypertension, Glickman Urological and
Kidney Institute, Cleveland Clinic

MOHAMMED A. RAFEY, MD, MS

Department of Nephrology and Hypertension,
Glickman Urological and Kidney Institute,
Cleveland Clinic

Beta-blockers for hypertension: Are they going out of style?

ABSTRACT

Although beta-blockers lower blood pressure in most patients, the outcomes of clinical hypertension trials of these drugs have been disappointing, and the value of beta-blockers in treating hypertensive patients who do not have compelling indications for them has been questioned. Until these drugs are proved beneficial, they should be used as antihypertensive therapy only in patients with compelling cardiac indications for them or as add-on agents in those with uncontrolled or resistant hypertension.

KEY POINTS

No evidence exists that beta-blockers prevent first episodes of cardiovascular events in patients with hypertension, and in some trials, outcomes were worse with beta-blockers than with antihypertensive drugs of other classes.

Younger hypertensive patients have hemodynamic characteristics that would seem to be amenable to beta-blocker therapy. However, most clinical trials of beta-blockers did not stratify patients by age.

Most trials of the antihypertensive effects of beta-blockers used atenolol (Tenormin), which is not an ideal representative of this class of drugs.

Newer beta-blockers with vasodilatory properties may overcome the adverse effect of increased peripheral vascular resistance that occurs with older agents such as atenolol.

IN RECENT YEARS the role of beta-blockers as a primary tool to treat hypertension has come under question. These drugs have shown disappointing results when used as antihypertensive therapy in patients without heart disease, ie, when used as primary prevention. At the same time, beta-blockers clearly reduce the risk of future cardiovascular events in patients who already have heart disease, eg, who already have had a myocardial infarction or who have congestive heart failure.

Several meta-analyses and a few clinical trials have shown that beta-blockers may have no advantage over other antihypertensive drugs, and in fact may not reduce the risk of stroke as effectively as other classes of blood pressure medications.

Why should this be? Is it that the patients in the antihypertensive trials were mostly older, and that beta-blockers do not work as well in older patients as in younger ones? Or does it have to do with the fact that atenolol (Tenormin) was the drug most often used in the trials? Would newer, different beta-blockers be better?

Hypertension experts currently disagree on how to interpret the available data, and this has led to conflict and confusion among clinicians as to the role of beta-blockers in managing hypertension. Current evidence suggests that older beta-blockers may not be the preferred first-line antihypertensive drugs for hypertensive patients who have no compelling indications for them (eg, heart failure, myocardial infarction, diabetes, high risk of coronary heart disease). However, newer beta-blockers with vasodilatory properties should be considered in cases of uncontrolled or resistant hypertension, especially in younger patients.

doi:10.3949/ccjm.76a.09030

Further, while controversy and debate continue over the benefits and adverse effects of one class of antihypertensive drugs vs another, it is indisputable that controlling arterial blood pressure to the recommended goal offers major protection against cardiovascular and renal events in patients with hypertension.^{1,2}

MECHANISM OF ACTION OF BETA-BLOCKERS

Beta-blockers effectively reduce blood pressure in both systolic-diastolic hypertension and isolated systolic hypertension.³⁻⁵ Exactly how is not known, but it has been proposed that they may do so by:

Reducing the heart rate and cardiac output. When catecholamines activate beta-1 receptors in the heart, the heart rate and myocardial contractility increase. By blocking beta-1 receptors, beta-blockers reduce the heart rate and myocardial contractility, thus lowering cardiac output and arterial blood pressure.⁶

Inhibiting renin release. Activation of the renin-angiotensin system is another major pathway that can lead to elevated arterial blood pressure. Renin release is mediated through the sympathetic nervous system via beta-1 receptors on the juxtaglomerular cells of the kidney. Beta-blockers can therefore lower blood pressure by inhibiting renin release.⁷

Inhibiting central nervous sympathetic outflow, thereby inducing presynaptic blockade, which in turn reduces the release of catecholamines.

Reducing venous return and plasma volume.

Generating nitric oxide, thus reducing peripheral vascular resistance (some agents).⁸

Reducing vasomotor tone.

Reducing vascular tone.

Improving vascular compliance.

Resetting baroreceptor levels.

Attenuating the pressor response to catecholamines with exercise and stress.

HETEROGENEITY OF BETA-BLOCKERS

Selectivity

Beta-blockers are not all the same. They can be classified into three categories.

Nonselective beta-blockers block both beta-1 and beta-2 adrenergic receptors. It is generally accepted that beta-blockers exert their primary antihypertensive effect by blocking beta-1 adrenergic receptors.⁶ Of interest, nonselective beta-blockers inhibit beta-2 receptors on arteries and thus cause an unopposed alpha-adrenergic effect, leading to increased peripheral vascular resistance.⁹ Examples of this category:

- Nadolol (Corgard)
- Pindolol (Visken)
- Propranolol (Inderal)
- Timolol (Blocadren).

Selective beta-blockers specifically block beta-1 receptors alone, although they are known to be nonselective at higher doses. Examples:

- Atenolol (Tenormin)
- Betaxolol (Kerlone)
- Bisoprolol (Zebeta)
- Esmolol (Brevibloc)
- Metoprolol (Lopressor, Toprol).

Beta-blockers with peripheral vasodilatory effects act either via antagonism of the alpha-1 receptor, as with labetalol (Normodyne) and carvedilol (Coreg),¹⁰ or via enhanced release of nitric oxide, as with nebivolol (Bystolic).⁸

Lipid and water solubility

The lipid solubility and water solubility of each beta-blocker determine its bioavailability and side-effect profile.

Lipid solubility determines the degree to which a beta-blocker penetrates the blood-brain barrier and thereby leads to central nervous system side effects such as lethargy, nightmares, confusion, and depression. Propranolol is highly lipid-soluble; metoprolol and labetalol are moderately so.

Water-soluble beta-blockers such as atenolol have less tissue permeation, have a longer half-life, and cause fewer central nervous system effects and symptoms.¹¹

Routes of elimination

Beta-blockers also differ in their route of elimination.

Atenolol and nadolol are eliminated by the kidney and require dose adjustment in patients with impaired renal function.^{12,13}

On the other hand, propranolol, meto-

The lipid solubility and water solubility of each beta-blocker determine its bioavailability and side-effect profile

prolol, labetalol, carvedilol, and nebivolol are excreted primarily via hepatic metabolism.¹³

■ BETA-BLOCKERS IN THE MANAGEMENT OF HYPERTENSION

Beta-blockers were initially used to treat arrhythmias, but by the early 1970s they were also widely accepted for managing hypertension.¹⁴ Their initial acceptance as one of the first-line classes of drugs for hypertension was based on their better side-effect profile compared with other antihypertensive drugs available at that time.

In the 1980s and 1990s, beta-blockers were listed as preferred first-line antihypertensive drugs along with diuretics in national hypertension guidelines.¹⁵ Subsequent updates of the guidelines favored diuretics as initial therapy and relegated all other classes of antihypertensive medications to be alternatives to diuretics.¹⁶ Although beta-blockers remain alternative first-line drugs in the latest guidelines (published in 2003; see reference 66), they are the preferred antihypertensive agents for patients with cardiac disease.

The current recommendations reflect the findings from hypertension trials in which patients with myocardial infarction and congestive heart failure had better cardiovascular outcomes if they received these drugs,^{17–19} including a lower risk of death.^{20,21} It was widely assumed that beta-blockers would also prevent first episodes of cardiovascular events.

However, to date, there is no evidence that beta-blockers are effective as primary prevention. Several large randomized controlled trials showed no benefit with beta-blockers compared with other antihypertensive drugs—in fact, there were more cardiovascular events with beta-blockers (see below).

Beta-blockers are well tolerated in clinical practice, although they can have side effects that include fatigue, depression, impaired exercise tolerance, sexual dysfunction, and asthma attacks.

Wiysonge et al²² analyzed how many patients withdrew from randomized trials of antihypertensive treatment because of drug-related adverse events. There was no significant difference in the incidence of fatigue, depressive symptoms, or sexual dysfunction with be-

ta-blockers compared with placebo, and trial participants on a beta-blocker were not statistically significantly more likely to discontinue treatment than those receiving a placebo in three trials with 22,729 participants (relative risk [RR] 2.34, 95% confidence interval [CI] 0.84–6.52).

■ THE CONTROVERSY: WHAT THE TRIALS SHOWED

Messerli et al²³ performed a meta-analysis published in 1998 that suggested that beta-blockers may not be as effective as diuretics in preventing cardiovascular events when used as first-line antihypertensive therapy in elderly patients. In 10 randomized controlled trials in 16,164 patients who were treated with either a diuretic or a beta-blocker (atenolol), blood pressure was normalized in two-thirds of diuretic-treated patients but only one-third of patients treated with atenolol as monotherapy. Diuretic therapy was superior with regard to all end points, and beta-blockers were found to be ineffective except in reducing cerebrovascular events.

The LIFE study (Losartan Intervention for Endpoint Reduction in Hypertension)²⁴ compared the angiotensin-receptor blocker losartan (Cozaar) and atenolol in 9,193 patients with hypertension and left ventricular hypertrophy. At 4 years of follow-up, the rate of primary cardiovascular events (death, myocardial infarction, or stroke) was lower in the losartan group than in the atenolol group. The difference was mainly due to a 25% lower incidence of stroke, which was statistically significant. The rates of myocardial infarction and death from cardiovascular causes were not significantly different between the two treatment groups. The systolic blood pressure was 1 mm Hg lower in the losartan group than in the atenolol group, which was statistically significant.

Carlberg et al²⁵ performed another important meta-analysis that questioned whether atenolol reduces rates of cardiovascular morbidity and death in hypertensive patients. The results were surprising: eight randomized controlled trials including more than 6,000 patients and comparing atenolol with placebo or no treatment showed no dif-

Atenolol and nadolol are eliminated by the kidney and need dose adjustment in patients with impaired renal function

ferences between the treatment groups with regard to the outcomes of all-cause mortality (RR 1.01, 95% CI 0.89–1.15), cardiovascular mortality (RR 0.99, 95% CI 0.83–1.18), or myocardial infarction (RR 0.99, 95% CI 0.83–1.19).

In addition, when atenolol was compared with other antihypertensives in five other randomized controlled trials that included more than 14,000 patients, those treated with atenolol had a higher risk of stroke (RR 1.30, 95% CI 1.12–1.50) and death (RR 1.13, 95% CI 1.02–1.25).

The ASCOT-BPLA trial (Anglo-Scandinavian Cardiac Outcomes Trial—Blood Pressure Lowering Arm)²⁶ had similar results. This trial compared the combination of atenolol plus the diuretic bendroflumethiazide against the combination of the calcium channel blocker amlodipine (Norvasc) plus the angiotensin-converting enzyme (ACE) inhibitor perindopril (Aceon). Although no significant difference was seen in the primary outcome of nonfatal myocardial infarction or fatal coronary heart disease (unadjusted hazard ratio [HR] with amlodipine-perindopril 0.90, 95% CI 0.79–1.02, $P = .1052$), the amlodipine-plus-perindopril group had significantly fewer strokes (327 vs 422, HR 0.77, 95% CI 0.66–0.89, $P = .0003$), fewer total cardiovascular events (1,362 vs 1,602, HR 0.84, 95% CI 0.78–0.90, $P = .0001$), and fewer deaths from any cause (738 vs 820; HR 0.89, 95% CI 0.81–0.99, $P = .025$).

Lindholm et al²⁷ performed a meta-analysis that included studies of selective beta-blockers (including atenolol) and nonselective beta-blockers, with a follow-up time of more than 2 years. Compared with placebo or no treatment, beta-blockers reduced the risk of stroke by 19% but had no effect on myocardial infarction or all-cause mortality. Compared with other antihypertensive drugs, beta-blockers were less than optimum, and the relative risk of stroke was 16% higher. Atenolol was the beta-blocker used in most of the randomized clinical trials included in this meta-analysis.

The Cochrane group²² found beta-blockers to be inferior to all other antihypertensive drugs with respect to the ability to lower the risk of stroke.

WHY WERE THE RESULTS SO DISAPPOINTING?

Problems with atenolol

Most of the trials in the meta-analyses discussed above used atenolol and other beta-blockers that had no vasodilatory properties.

Further, in most of the trials atenolol was used in a once-daily dosage, whereas ideally it needs to be taken more frequently, based on its pharmacokinetic and pharmacodynamic properties (a half-life of 6–9 hours).³ Neutel et al²⁸ confirmed that atenolol, when taken once daily, leaves the patient unprotected in the last 6 hours of a 24-hour period, as demonstrated by 24-hour ambulatory blood pressure monitoring. It is possible that this short duration of action of atenolol may have contributed to the results observed in clinical trials that used atenolol to treat hypertension.

Differences between older and younger patients

Another possible reason for the disappointing results is that the trials included many elderly patients, in whom beta-blockers may not be as effective. The pathophysiology of hypertension in younger people is different from that in older patients.²⁹ Hemodynamic characteristics of younger hypertensive patients include a high cardiac output and hyperdynamic circulation with a low pulse pressure, while older patients have lower arterial compliance with an elevated vascular resistance.

The notion of choosing antihypertensive medications on the basis of age and age-related pathophysiology is supported by several clinical studies. Randomized controlled trials appear to show that beta-blockers are effective in younger hypertensive patients.³⁰

Conversely, the CAFE (Conduit Artery Function Evaluation) trial,³¹ a substudy of the main ASCOT trial,²⁶ indicated that beta-blocker-based therapy was less effective in reducing central aortic pressure than were regimens based on an ACE inhibitor or a calcium channel blocker.

The CAFE researchers recruited 2,073 patients from five ASCOT centers and used radial artery applanation tonometry and pulse-wave analysis to derive central aortic pressures and hemodynamic indices during

**Once-daily
atenolol leaves
the patient
unprotected
for the last 6
hours**

Beta-blockers are better than placebo in younger patients but not older patients





FIGURE 1. Risk ratios for the composite outcome (death, stroke, or myocardial infarction) in patients under age 60 (top) and patients age 60 and older (bottom) receiving beta-blockers or placebo. The size of the boxes represents the number of participants who experienced a cardiovascular event. Trials are listed in order of publication. CI = confidence interval.

KHAN N, MCALISTER FA. RE-EXAMINING THE EFFICACY OF BETA-BLOCKERS FOR THE TREATMENT OF HYPERTENSION: A META-ANALYSIS. CMAJ 2006; 174:1737–1742. COPYRIGHT © 2006 THE CANADIAN MEDICAL ASSOCIATION JOURNAL. THIS WORK IS PROTECTED BY COPYRIGHT AND THE MAKING OF THIS COPY WAS WITH THE PERMISSION OF ACCESS COPYRIGHT. ANY ALTERATION OF ITS CONTENT OR FURTHER COPYING IN ANY FORM WHATSOEVER IS STRICTLY PROHIBITED UNLESS OTHERWISE PERMITTED BY LAW.

Beta-blockers are as good as other classes in younger patients but not older patients

Patients younger than 60 years



Patients 60 years and older




FIGURE 2. Risk ratios for the composite outcome (death, stroke, or myocardial infarction) in patients under age 60 (top) and patients age 60 and older (bottom) receiving beta-blockers or other antihypertensive drugs. The size of the boxes represents the number of participants who experienced a cardiovascular event. Trials are listed in order of publication. CI = confidence interval.

KHAN N, MCALISTER FA. RE-EXAMINING THE EFFICACY OF BETA-BLOCKERS FOR THE TREATMENT OF HYPERTENSION: A META-ANALYSIS. CMAJ 2006; 174:1737-1742. COPYRIGHT © 2006 THE CANADIAN MEDICAL ASSOCIATION JOURNAL. THIS WORK IS PROTECTED BY COPYRIGHT AND THE MAKING OF THIS COPY WAS WITH THE PERMISSION OF ACCESS COPY-RIGHT. ANY ALTERATION OF ITS CONTENT OR FURTHER COPYING IN ANY FORM WHATSOEVER IS STRICTLY PROHIBITED UNLESS OTHERWISE PERMITTED BY LAW.

study visits up to a period of 4 years. Although the two treatment groups achieved similar brachial systolic blood pressures, the central aortic systolic pressure was 4.3 mm Hg lower in the amlodipine group (95% CI 3.3–5.4; $P < .0001$), and the central aortic pulse pressure was 3.0 mm Hg lower (95% CI 2.1–3.9; $P < .0001$).

Khan and McAlister³² performed a meta-analysis in which they stratified clinical trials by the age of the study participants: those enrolling patients younger than 60 years and those enrolling patients 60 years and older. Included were 145,811 patients from 21 hypertension trials. In placebo-controlled trials,^{30,33–38} beta-blockers reduced the risk of major cardiovascular events in younger patients (RR 0.86, 95% CI 0.74–0.99, based on 794 events in 19,414 patients) but not in older patients (RR 0.89, 95% CI 0.75–1.05, based on 1,115 events in 8,019 patients) (FIGURE 1). In active comparator trials,^{24,33,36,39–46} beta-blockers were similar in efficacy to other antihypertensive agents in younger patients (1,515 events in 30,412 patients, RR 0.97, 95% CI 0.88–1.07) but not in older patients (7,405 events in 79,775 patients, RR 1.06, 95% CI 1.01–1.10) (FIGURE 2), with the excess risk being particularly marked for strokes (RR 1.18, 95% CI 1.07–1.30).

In view of these findings, Khan and McAlister³² proposed that beta-blockers should not be the first-line drugs for elderly hypertensive patients who do not have any other compelling indications for this class of drugs.

Pulse-wave dyssynchrony

Bangalore et al⁴⁷ offer an interesting hypothesis to explain the probable adverse effect of beta-blockers. Their theory concerns the effect of these drugs on the arterial pulse wave.

Normally, with each contraction of the left ventricle during systole, an arterial pulse wave is generated and propagated forward to the peripheral arteries. This wave is then reflected back to the heart from the branching points of peripheral arteries. The final form of the pressure wave at the aortic root is a synchronized summation of the forward-traveling wave and the backward-reflected wave.

In healthy people with normal arteries, the reflected wave merges with the forward-traveling wave in diastole and augments coronary blood flow. In patients whose arteries are stiff due to aging or vascular comorbidities, the reflected wave returns faster and merges with the incident wave in systole, resulting in higher left ventricular afterload and less coronary perfusion.⁴⁸

Bangalore et al⁴⁷ propose that artificially reducing the heart rate with beta-blockers may further dyssynchronize the pulse wave, adversely affecting coronary perfusion and leading to an increased risk of cardiovascular events and death.

Metabolic side effects

Older beta-blockers, and especially atenolol, have well-known metabolic adverse effects, particularly impairment of glycemic control. This adverse effect appears to occur only with beta-blockers that do not possess vasodilatory properties and thus increase peripheral vascular resistance, which results in lower glucose availability and reduced uptake by skeletal muscles.⁴⁹

Bangalore et al⁵⁰ evaluated the effect of beta-blockers in a meta-analysis of 12 studies in 94,492 patients followed up for more than 1 year. Beta-blocker therapy resulted in a 22% higher risk of new-onset diabetes mellitus (RR 1.22, 95% CI 1.12–1.33) than with other non-diuretic antihypertensive agents.

Of note, however, the meta-analysis did not show a significantly higher risk of the onset of diabetes with propranolol or metoprolol than with other nondiuretic antihypertensives when studies of these beta-blockers were separated from atenolol-based studies.

Further, the United Kingdom Prospective Diabetes Study⁴⁰ found that cardiovascular outcomes in patients with good blood pressure control were similar when atenolol-based therapy was compared with therapy with the ACE inhibitor captopril (Capoten).

A meta-analysis conducted by Balamuthusamy et al⁵¹ in 2009 found no higher risk of stroke in patients with hypertension and diabetes mellitus who received beta-blockers than in those who received other antihypertensive medications. However, beta-blockers were associated with a higher risk of death from cardiovascular causes (RR 1.39, 95% CI 1.07–1.804; $P < .01$) compared with renin-angiotensin blockade.

Beta-blockers are well tolerated in clinical practice, despite their side effects

■ NEWER BETA-BLOCKERS MAY BE BETTER

In the United States, more than 40 million prescriptions for atenolol are written every year, making it by far the most commonly used beta-blocker for the treatment of hypertension.⁵² It is clear, however, that atenolol is not an ideal representative of this class of antihypertensive medications.

Preliminary data from studies of newer beta-blockers that possess beneficial vasodilatory properties are encouraging. Animal studies and preliminary human studies find that these new-generation beta-blockers cause fewer adverse metabolic effects and improve endothelial function, measures of arterial stiffness, and cardiovascular outcomes.

Carvedilol

Carvedilol is a nonselective beta-blocker with vasodilatory effects that are thought to be due to its ability to concurrently block alpha-1 receptors in addition to beta receptors.⁵³ In experiments in vitro and in trials in patients with diabetes and hypertension, carvedilol increased endothelial vasodilation and reduced inflammation and platelet aggregation. These effects may be achieved through antioxidant actions, thereby preserving nitric oxide bioactivity.^{54,55}

In the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) trial,⁵⁶ carvedilol was associated with better maintenance of glycemic control in diabetic hypertensive patients than was metoprolol. Insulin sensitivity improved with carvedilol but not with metoprolol, and fewer patients on carvedilol progressed to microalbuminuria.

Nebivolol

Nebivolol is a novel selective beta-blocker with a much higher affinity for beta-1 adrenergic receptors than for beta-2 adrenergic receptors. Among all the beta-blockers in clinical use today, nebivolol has the highest selectivity for beta-1 receptors.⁸

Nebivolol causes vasodilation through activation of the L-arginine/nitric oxide pathway.⁵⁷⁻⁵⁹ Blockade of synthesis of nitric oxide leads to local arterial stiffness. Endothelial dysfunction is characterized by decreased bioavailability of nitric oxide and has been

shown to be a strong predictor of cardiovascular outcomes. By generating nitric oxide, nebivolol reduces peripheral vascular resistance, overcoming a significant side effect of earlier beta-blockers that lowered blood pressure but ultimately increased peripheral vascular tone and resistance.⁸

In an experiment in a bovine model,⁶⁰ nebivolol significantly reduced the pulse-wave velocity (a measure of arterial stiffness), while atenolol had no effect. Moreover, evidence for the role of the L-arginine/nitric oxide pathway in the vasodilatory effect of nebivolol was demonstrated by co-infusion of *N*^G-monomethyl-L-arginine, a specific endothelial nitric oxide synthetase inhibitor that attenuated the reduction of pulse-wave velocity by nebivolol.

In studies in hypertensive patients, nebivolol was associated with a better metabolic profile than atenolol, with none of the adverse effects on insulin sensitivity that atenolol had.⁶¹ In the Study of Effects of Nebivolol Interventions on Outcomes and Rehospitalization in Seniors With Heart Failure (SENIORS) trial, significantly fewer patients receiving nebivolol died or were admitted to the hospital for cardiovascular reasons compared with those receiving placebo.⁶²

Although these findings are encouraging, we do not yet know if these effects will translate into a significant reduction in cardiovascular outcomes in clinical trials. Large, prospective hypertension outcome trials, particularly to evaluate primary prevention of cardiovascular outcomes, are needed for an evidence-based approach to using the newer beta-blockers as preferred first-line therapy for hypertension.

■ WHAT RECENT GUIDELINES SAY ABOUT BETA-BLOCKERS

The British National Institute for Health and Clinical Excellence and the British Hypertension Society, in their 2004 guidelines, recommended beta-blockers as one of several first-line antihypertensive medications in young, nonblack patients.⁶³ On the other hand, they advised clinicians to be aware of the reported increase in onset of diabetes mellitus in patients treated with these medications. After

Preliminary data on newer beta-blockers are encouraging

the LIFE²⁴ and ASCOT²⁶ study results were published, these guidelines were amended to exclude beta-blockers as preferred routine initial therapy for hypertension.⁶⁴

More recently, the 2007 European Society of Hypertension and European Society of Cardiology reconsidered the role of beta-blockers, recommending them as an option in both initial and subsequent antihypertensive treatment strategies.⁶⁵

The current guidelines from the National

Heart, Lung, and Blood Institute,⁶⁶ which were published in 2003, were highly influenced by the results of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT),² and favor diuretics as the first-line therapy. However, they indicate that beta-blockers are a suitable alternative, particularly when a compelling cardiac indication is present.⁵³ We hope that the next update, expected late in 2009, will re-address this issue in the light of more recent data. ■

REFERENCES

1. Staessen JA, Wang JG, Thijs L. Cardiovascular protection and blood pressure reduction: a meta-analysis. *Lancet* 2001; 358:1305–1315.
2. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA* 2002; 288:2981–2997.
3. Neutel JM, Smith DH, Ram CV, et al. Application of ambulatory blood pressure monitoring in differentiating between antihypertensive agents. *Am J Med* 1993; 94:181–187.
4. Materson BJ, Reda DJ, Cushman WC, et al. Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. *N Engl J Med* 1993; 328:914–921.
5. Psaty BM, Smith NL, Siscovick DS, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta-analysis. *JAMA* 1997; 277:739–745.
6. Frishman W, Silverman R. Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 2. Physiologic and metabolic effects. *Am Heart J* 1979; 97:797–807.
7. Garrett BN, Kaplan NM. Plasma renin activity suppression: duration after withdrawal from beta-adrenergic blockade. *Arch Intern Med* 1980; 140:1316–1318.
8. Pedersen ME, Cockcroft JR. The latest generation of beta-blockers: new pharmacologic properties. *Curr Hypertens Rep* 2006; 8:279–286.
9. Man in't Veld AJ, Van den Meiracker AH, Schalekamp MA. Do beta-blockers really increase peripheral vascular resistance? Review of the literature and new observations under basal conditions. *Am J Hypertens* 1988; 1:91–96.
10. Pearce CJ, Wallin JD. Labetalol and other agents that block both alpha- and beta-adrenergic receptors. *Cleve Clin J Med* 1994; 61:59–69.
11. Dimsdale JE, Newton RP, Joist T. Neuropsychological side effects of beta-blockers. *Arch Intern Med* 1989; 149:514–525.
12. Agarwal R. Supervised atenolol therapy in the management of hemodialysis hypertension. *Kidney Int* 1999; 55:1528–1535.
13. Sica DA, Black HR. Pharmacologic considerations in the positioning of beta-blockers in antihypertensive therapy. *Curr Hypertens Rep* 2008; 10:330–335.
14. Prichard BN, Gillam GP. Use of propranolol (Inderal) in treatment of hypertension. *Br Med J* 1964; 19: 2:725–727.
15. The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V). *Arch Intern Med* 1993; 153:154–183.
16. Moser M. Evolution of the treatment of hypertension from the 1940s to JNC V. *Am J Hypertens* 1997; 10:25–85.
17. Houghton T, Freemantle N, Cleland JG. Are beta-blockers effective in patients who develop heart failure soon after myocardial infarction? A meta-regression analysis of randomised trials. *Eur J Heart Fail* 2000; 2:333–340.
18. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. *Lancet* 1999; 353:9–13.
19. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). *Lancet* 1999; 353:2001–2007.
20. Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. *Prog Cardiovasc Dis* 1985; 27:335–371.
21. Brophy JM, Joseph L, Rouleau JL. Beta-blockers in congestive heart failure. A Bayesian meta-analysis. *Ann Intern Med* 2001; 134:550–560.
22. Wiysonge CS, Bradley H, Mayosi BM, et al. Beta-blockers for hypertension. *Cochrane Database Syst Rev* 2007; CD002003.
23. Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. *JAMA* 1998; 279:1903–1907.
24. Dahlöf B, Devereux RB, Kjeldsen SE, et al for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. *Lancet* 2002; 359:995–1003.
25. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? *Lancet* 2004; 364:1684–1689.
26. Dahlöf B, Sever PS, Poulter NR, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. *Lancet* 2005; 366:895–906.
27. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first choice in the treatment of primary hypertension? A meta-analysis. *Lancet* 2005; 366:1545–1553.
28. Neutel JM, Schnaper H, Cheung DG, Graettinger WF, Weber MA. Antihypertensive effects of beta-blockers administered once daily: 24-hour measurements. *Am Heart J* 1990; 120:166–171.
29. Franklin SS, Gustin W, Wong ND, et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. *Circulation* 1997; 96:308–315.
30. The IPPPSH Collaborative Group. Cardiovascular risk and risk factors in a randomized trial of treatment based on the beta-blocker oxprenolol: the International Prospective Primary Prevention Study in Hypertension (IPPPSH). *J Hypertens* 1985; 3:379–392.
31. Williams B, Lacy PS, Thom SM, et al; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. *Circulation* 2006; 113: 1213–1225.
32. Khan N, McAlister FA. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis. *CMAJ* 2006; 174:1737–1742.
33. Medical Research Council Working Party. MRC trial of treatment of

- mild hypertension: principal results. *BMJ* 1985; 291:97–104.
34. **Coope J, Warrender TS.** Randomised trial of treatment of hypertension in elderly patients in primary care. *BMJ* 1986; 293:1145–1151.
 35. **Dahlöf B, Lindholm LH, Hansson L, et al.** Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). *Lancet* 1991; 338:1281–1285.
 36. **MRC Working Party.** Medical Research Council trial of treatment of hypertension in older adults: principal results. *BMJ* 1992; 304:405–412.
 37. **The Dutch TIA Study Group.** Trial of secondary prevention with atenolol after transient ischemic attack or nondisabling ischemic stroke. *Stroke* 1993; 24:543–548.
 38. **Eriksson S, Olofsson B-O, Wester P-O, for the TEST Study Group.** Atenolol in secondary prevention after stroke. *Cerebrovasc Dis* 1995; 5:21–25.
 39. **Wilhelmsen L, Berglund G, Elmfeldt D, et al.** Beta-blockers versus diuretics in hypertensive men: main results from the HAPPHY trial. *J Hypertens* 1987; 5:561–572.
 40. **UK Prospective Diabetes Study Group.** Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. *BMJ* 1998; 317:713–720.
 41. **Hansson L, Lindholm LH, Niskanen L, et al.** Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPP) randomised trial. *Lancet* 1999; 353:611–616.
 42. **Lanchetti A, Bond MG, Henning M, et al.** Calcium antagonist lacidipine slow down progression of asymptomatic carotid atherosclerosis. Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. *Circulation* 2002; 106:2422–2427.
 43. **Hansson L, Lindholm LH, Ekblom T, et al.** Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity in the Swedish Trial in Old Patients with Hypertension-2 study. *Lancet* 1999; 354:1751–1756.
 44. **Hansson L, Hedner T, Lund-Johansen P, et al.** Randomised trial of effects of calcium antagonists compared with diuretics and β blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. *Lancet* 2000; 356:359–365.
 45. **Pepine CJ, Handsberg EM, Cooper-DeHoff RM, et al.** A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. *JAMA* 2003; 290:2805–2816.
 46. **Black HR, Elliott WJ, Grandits G, et al.** Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) Trial. *JAMA* 2003; 289:2073–2082.
 47. **Bangalore S, Sawhney S, Messerli FH.** Relation of beta-blocker-induced heart rate lowering and cardioprotection in hypertension. *J Am Coll Cardiol* 2008; 52:1482–1489.
 48. **Boutouyrie P, Vermeersch S, Laurent S, Briet M.** Cardiovascular risk assessment through target organ damage: role of carotid to femoral pulse wave velocity. *Clin Exp Pharmacol Physiol* 2008; 35:530–533.
 49. **Kveiborg B, Christiansen B, Major-Petersen A, Torp-Pedersen C.** Metabolic effects of beta-adrenoceptor antagonists with special emphasis on carvedilol. *Am J Cardiovasc Drugs* 2006; 6:209–217.
 50. **Bangalore S, Parkar S, Grossman E, Messerli FH.** A meta-analysis of 94,492 patients with hypertension treated with beta-blockers to determine the risk of new-onset diabetes mellitus. *Am J Cardiol* 2007; 100:1254–1262.
 51. **Balamuthusamy S, Molnar J, Adigopula S, Arora R.** Comparative analysis of beta-blockers with other antihypertensive agents on cardiovascular outcomes in hypertensive patients with diabetes mellitus: a systematic review and meta-analysis. *Am J Ther* 2009; 16:133–142.
 52. **Berenson A.** Big drug makers see sales decline with their image. *New York Times* 2005 Nov 14.
 53. **Bristow MR.** Beta-adrenergic receptor blockade in chronic heart failure. *Circulation* 2000; 101:558–569.
 54. **Giugliano D, Marfella R, Acampora R, Giunta R, Coppola L, D'Onofrio F.** Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. *Diabetes Care* 1998; 21:631–636.
 55. **Lopez BL, Christopher TA, Yue TL, Ruffolo R, Feuerstein GZ, Ma XL.** Carvedilol, a new beta-adrenoreceptor blocker antihypertensive drug, protects against free-radical-induced endothelial dysfunction. *Pharmacology* 1995; 51:165–173.
 56. **Bakris GL, Fonseca V, Katholi RE, et al; GEMINI Investigators.** Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA* 2004; 292:2227–2236.
 57. **Georgescu A, Pluteanu F, Flonta ML, Badila E, Dorobantu M, Popov D.** The cellular mechanisms involved in the vasodilator effect of nebivolol on the renal artery. *Eur J Pharmacol* 2005; 508:159–166.
 58. **Kalinowski L, Dobrucki LW, Szczepanska-Konkel M, et al.** Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action. *Circulation* 2003; 107:2747–2752.
 59. **Cockcroft JR, Chowiecnyk PJ, Brett SE, et al.** Nebivolol vasodilates human forearm vasculature: evidence for an L-arginine/NO-dependent mechanism. *J Pharmacol Exp Ther* 1995; 274:1067–1071.
 60. **McEniery CM, Schmitt M, Qasem A, et al.** Nebivolol increases arterial distensibility in vivo. *Hypertension* 2004; 44:305–310.
 61. **Poirier L, Cleroux J, Nadeau A, Lacourciere Y.** Effects of nebivolol and atenolol on insulin sensitivity and haemodynamics in hypertensive patients. *J Hypertens* 2001; 19:1429–1435.
 62. **Flather MD, Shibata MC, Coats AJ, et al; SENIORS Investigators.** Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). *Eur Heart J* 2005; 26:215–225.
 63. **Williams B, Poulter NR, Brown MJ, et al; BHS guidelines working party, for the British Hypertension Society.** British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. *BMJ* 2004; 328:634–640.
 64. **Sever P.** New hypertension guidelines from the National Institute for Health and Clinical Excellence and the British Hypertension Society. *J Renin Angiotensin Aldosterone Syst* 2006; 7:61–63.
 65. **Mancia G, De Backer G, Dominiczak A, et al; Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology.** 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). *J Hypertens* 2007; 25:1105–1187.
 66. **Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee.** The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA* 2003; 289:2560–2572.

ADDRESS: Mohammed A. Rafey, MD, MS, Department of Nephrology and Hypertension, Glickman Urological and Kidney Institute, Q7, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail rafeym@ccf.org.